News
Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 ...
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" ...
Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...
Eli Lilly (LLY) stock in focus as Texas sues the company for alleged bribery related to weight loss drugs like Zepbound and ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
1don MSN
If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today
Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has ...
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback